Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big savings?

The price of Humira rose 470% in the 20 years following its launch in 2003 to reach upward of $84,000 annually. List prices of Humira biosimilars are as much as 85% lower.

Analysts predict that sales of Humira will fall to $14.1 billion this year, before dropping to $8.7 billion in 2024 and $6.1 billion the following year, according to Refinitiv data.

UnitedHealth Group’s OptumRx will put biosimilar versions of Abbvie’s pricey rheumatoid arthritis drug Humira “in the same position as the brand” on the PBM’s formulary in 2023.

AbbVie’s precursor, Abbott Laboratories, launched Humira in 2003 at $522 per two-week 40-milligram syringe. Within 10 years, that price jumped to $1,024 per syringe, according to a House ...

The new drug, Amjevita, will be sold at a list price from $1,558 to $3,288 for a 40 milligram, two-week supply of the injectable drug, Amgen said, representing discounts of 5% or 55% from Humira's ...

A report from the inspector general of HHS examines the latest trends since several biosimilar versions of Humira were launched in the U.S. in 2023.

The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign.

After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.

CVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will recommend ...

Amgen’s long-awaited Humira biosimilar, Amjevita, has finally hit the market. After years of sitting on the biosimilar, which won an FDA approval in 2016, Amgen is ready to make waves.

AbbVie's arthritis treatment Humira and other biologics account for almost half of annual U.S. drug spending—but just 2% of prescriptions.